Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

ConclusionFurther studies to identify predictive factors for the development of irAEs are required to provide relevant patient care and maximize the therapeutic benefits of ICIs.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research